Innoviva, Inc. INVA
19.08 USD +0.08 (+0.42%)
At closeNov 11, 2026, 4:01 AM EST
19.31 +0.23 +1.21%
Pre-market · Nov 11, 4:01 AM ET
18.80 Day range 20.10
18.70 52-week range 25.15
- YTD
- -4.55%
- 1 year
- -8.58%
News
zacks.com Is Innoviva (INVA) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
zacks.com INVA or MRK: Which Is the Better Value Stock Right Now? Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value…
benzinga.com Oppenheimer Maintains Outperform on Innoviva, Lowers Price Target to $34 Oppenheimer analyst Les Sulewski maintains Innoviva (NASDAQ:INVA) with a Outperform and lowers the price target from $35 to $34.
zacks.com Innoviva (INVA) Tops Q3 Earnings Estimates Innoviva (INVA) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.08 per share a year ago.
businesswire.com Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and…